MedTrace Logo

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

NCT07243964 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2025-11-24

No results posted yet for this study

Summary

By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).

Conditions

  • Lung Diseases

Interventions

OTHER

longitudinal changes in multi-omics profiling of peripheral blood

This study investigates the associations between longitudinal changes in multi-omics profiling of peripheral blood-including cell-free DNA, single-cell transcriptomics, proteomics, and metabolomics-and the development of acute lung allograft dysfunction(ALAD) and chronic lung allograft dysfunction(CLAD) in lung transplant recipients at various postoperative time points.

Sponsors & Collaborators

  • Chang Chen

    lead OTHER

Principal Investigators

  • Chang Chen, MD,PHD · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2029-12-31
Completion
2030-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07243964 on ClinicalTrials.gov